Breast and ovarian cancers pose huge and unsolved challenges to the medical profession. Breast cancer is the most common cancer in women in the EU: more than 332,000 women are diagnosed with breast cancer each year and a woman dies every 6 minutes from this disease.
Ovarian cancer, whilst far less common than breast cancer, is often diagnosed when the disease is at an advanced stage and has spread to other areas of the body resulting in poor prognosis. More than 60% of ovarian cancer patients die within the first 5 years after diagnosis.
The research project EpiFemCare will use state-of-the-art technologies in epigenetics, next generation sequencing and data management to develop blood tests with the aim of replacing current methods of cancer detection and improving subsequent patient care.
It aims to reduce by 50% the number of women who receive a diagnosis of breast or ovarian cancer when that cancer is already advanced, reduce by 50% the number of women who receive unnecessary long-term chemotherapy, and reduce the number of women dying from these female cancers by 20%.
GATC Biotech will manage sample processing, i.e. the DNA isolation from serum and the reduced representation bisulfite sequencing from serum derived DNA.
University College London http://www.ucl.ac.uk
Univerzita Karlova v Praze http://www.cuni.cz
Ludwig Maximilians Universität München http://www.uni-muenchen.de
GATC Biotech AG http://www.gatc-biotech.com
Genedata AG http://www.genedata.com
Euram Limited http://www.euram.ltd.uk
Interested in further information about the project including videos in other languages? Visit epifemcare.eu.
The EpiFemCare project is partially funded by the European Union Seventh Framework Programme for Research and Innovation (FP7).